share_log

HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target

Moomoo 24/7 ·  Apr 23 06:28

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $10 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment